Oxford Biomedica (LON:OXB) Trading Down 5.1% – Here’s What Happened

Posted by Alanna Baker on Sep 2nd, 2026

Oxford Biomedica plc (LON:OXB – Get Free Report)’s share price dropped 5.1% during trading on Wednesday . The company traded as low as GBX 424 and last traded at GBX 424. 2,402,807 shares traded hands during mid-day trading, an increase of 122% from the average session volume of 1,081,424 shares. The stock had previously closed at GBX 447.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on OXB. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 8.27 price target on shares of Oxford Biomedica in a research report on Tuesday, June 2nd. Royal Bank Of Canada reissued an “outperform” rating and set a GBX 900 price objective on shares of Oxford Biomedica in a report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 595 target price on shares of Oxford Biomedica in a report on Wednesday. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, Oxford Biomedica has a consensus rating of “Moderate Buy” and a consensus target price of GBX 580.85.

Get Our Latest Analysis on Oxford Biomedica

Oxford Biomedica Stock Performance

The company’s fifty day simple moving average is GBX 566.92 and its 200 day simple moving average is GBX 606.44. The company has a current ratio of 2.20, a quick ratio of 1.67 and a debt-to-equity ratio of 162.16. The stock has a market capitalization of £513.20 million, a P/E ratio of -15.75 and a beta of 1.10.

Oxford Biomedica Company Profile

(Get Free Report)

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.